← Return to Intermittent Hormone Therapy (IHT): How is it working for you?

Discussion

Intermittent Hormone Therapy (IHT): How is it working for you?

Prostate Cancer | Last Active: 3 hours ago | Replies (47)
Comment receiving replies
@ava11

Journal of American Medical Association (JAMA) Oncology, March 7, 2024 issue has an interesting article:
"Efficacy and Safety of Radiotherapy Plus Relugolix in Men with Localized or Advanced Prostate Cancer"
It was published March 7,2024, so it is recent. A friend of mine at UCI and Immunology professor sent it to me. on my iPhone.
I am a legacy computer guy and don't know how to post a link to thar article here. But I will figure out later or ask my grandson to do that!
It is a randomized trial, somewhat rare, because it is expensive. Compares with other drugs and short vs long term ADT.

Jump to this post

Replies to "Journal of American Medical Association (JAMA) Oncology, March 7, 2024 issue has an interesting article: "Efficacy..."
heavyphil | @heavyphil | Dec 18, 2024

Good article, Ava….unfortunately it doesn’t shed any light on treatment outcomes with 24 weeks vs 48 weeks if Orgovyx; the main thrust is the safety and efficacy of the ADT and how fast it induces castrate levels and recovery of T after stopping.
It did not touch on who fared better in terms of PSA suppression between the two groups - which is what we have been kicking back and forth for a while now.
Maybe the next article in the series will address that issue🤞🤞

VIEW AND REPLY